BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 16565470)

  • 1. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
    Esbenshade TA; Fox GB; Cowart MD
    Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
    Witkin JM; Nelson DL
    Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
    Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
    Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keynote review: histamine H3 receptor antagonists reach out for the clinic.
    Celanire S; Wijtmans M; Talaga P; Leurs R; de Esch IJ
    Drug Discov Today; 2005 Dec; 10(23-24):1613-27. PubMed ID: 16376822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
    Leurs R; Bakker RA; Timmerman H; de Esch IJ
    Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3 receptor antagonists/inverse agonists as anti-obesity agents.
    Hancock AA
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine H3 receptor antagonists: from target identification to drug leads.
    Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T
    Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
    Onodera K; Watanabe T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine H3 and H4 receptors as novel drug targets.
    Tiligada E; Zampeli E; Sander K; Stark H
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of histamine H3 receptor antagonists in dementias.
    Chazot PL
    Drug News Perspect; 2010 Mar; 23(2):99-103. PubMed ID: 20369074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
    Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
    Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
    J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine H3 receptors and sleep-wake regulation.
    Lin JS; Sergeeva OA; Haas HL
    J Pharmacol Exp Ther; 2011 Jan; 336(1):17-23. PubMed ID: 20864502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
    Brioni JD; Esbenshade TA; Garrison TR; Bitner SR; Cowart MD
    J Pharmacol Exp Ther; 2011 Jan; 336(1):38-46. PubMed ID: 20864505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new class of histamine H3 receptor antagonists derived from ligand based design.
    Roche O; Rodríguez Sarmiento RM
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases.
    Sadek B; Saad A; Sadeq A; Jalal F; Stark H
    Behav Brain Res; 2016 Oct; 312():415-30. PubMed ID: 27363923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.